Autopsy report · NCT00609544

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

“Unable to enroll patients”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Regeneron Pharmaceuticals

Sponsor type

Industry

Conditions

Chronic Kidney Disease; Anemia

Interventions

Rilonacept

Participants

0

Sites

27

Countries

United States

Trials that died the same way

• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
  “Unable to enroll appropriate patients” (96% match in meaning)
• Peppermint Oil for Urinary Retention
  “Difficulty enrolling patients” (90% match in meaning)
• The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision
  “Unable to enroll more patients” (89% match in meaning)
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (87% match in meaning)
• Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
  “Unable to enroll patients, no longer at institution.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.